Tumour‐to‐tumour metastasis from papillary thyroid carcinoma with <i>BRAF</i> mutation to lung adenocarcinoma with <i>EGFR</i> mutation: the utility of mutation‐specific antibodies

Katsuya, Yuki; Yoshida, Akihiko; Watanabe, Shun‐ichi; Tsuta, Koji

doi:10.1111/his.12643

Cited by 12 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive and negative predictive values of FNAB in metastases to the thyroid gland were 89% and 93%, respectively. The application of molecular markers (e.g., the application of BRAF growth promoter in thyroid papillary carcinoma) and IHC (e.g., the application of CD-10 in RCC) may be further helpful in the diagnosis of FNAB [ 57 , 58 , 59 , 60 ]. Therefore, patients with previous or present extrathyroid malignant tumors should be regarded as having potential intrathyroidal metastasis when thyroid nodules or diffuse thyroid infiltration are found via ultrasound.…”

Section: Diagnosismentioning

confidence: 99%

Metastases to the Thyroid Gland: What Can We Do?

Tang

Wang

2022

Cancers

View full text Add to dashboard Cite

Metastases to the thyroid gland arise from other malignant tumors such as renal cell carcinoma, colorectal cancer, lung cancer, and breast cancer. In clinical practice, the incidence is low, and the symptoms are not specific, so it is often missed and misdiagnosed. It is finally diagnosed via the comprehensive application of many diagnostic methods, such as ultrasound, fine-needle aspiration biopsy, and immunohistochemistry analysis. Surgery-based comprehensive treatment is often adopted, but because it is usually in the late stage of the primary tumor, the prognosis is poor. In order to better understand the related characteristics of thyroid metastatic cancer and then improve the clinical diagnosis and treatment and the prognosis of patients, in this paper, we systematically summarize the research status of thyroid metastatic cancer.

show abstract

Section: Diagnosismentioning

confidence: 99%

Metastases to the Thyroid Gland: What Can We Do?

Tang

Wang

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Fine needle aspiration cytology (FNAC) can often be of assistance 55,56. In the setting of metastatic lesions to the thyroid, FNAC positive and negative predictive values of 89 and 93%, respectively, have been reported, and application of molecular markers (e.g., the BRAF growth promoter in papillary thyroid cancer) and immunohistochemistry may be of further help (e.g., CD-10 in RCC) 25,57–59. There limitations of cytology are acknowledged 29,56,60.…”

Section: Preoperative Investigationmentioning

confidence: 99%

Metastasis to the Thyroid Gland: A Critical Review

et al. 2016

View full text Add to dashboard Cite

BackgroundMetastasis to the thyroid gland from nonthyroid sites is an uncommon clinical presentation in surgical practice. The aim of this review was to assess its incidence management and outcomes.MethodsA literature review was performed to identify reports of metastases to the thyroid gland. Both clinical and autopsy series were included.ResultsMetastases to the gland may be discovered at the time of diagnosis of the primary tumor, after preoperative investigation of a neck mass, or on histologic examination of a thyroidectomy specimen. The most common primary tumors in autopsy studies are from the lung. In clinical series, renal cell carcinoma is most common. For patients with widespread metastases in the setting of an aggressive malignancy, surgery is rarely indicated. However, when patients present with an isolated metastasis diagnosed during follow-up of indolent disease, surgery may achieve control of the central neck and even long-term cure. Other prognosticators include features of the primary tumor, time interval between initial diagnosis and metastasis, and extrathyroid extent of disease.ConclusionsIn patients with thyroid metastases, communication among clinicians treating the thyroid and the index primary tumor is essential. The setting is complex, and decisions must be made considering the features of the primary tumor, overall burden of metastases, and comorbidities. Careful balancing of these factors influences individualized approaches.

show abstract

“…Papillary thyroid carcinoma (PTC), the most prevalent histology subtype (80% of cases), and its incidence have been increased a lot over the past few decades [ 2 , 3 ]. Multifocal lesions are one of clinical characteristics of PTC and provide a power evidence of lymph node invasion and distant metastasis [ 4 , 5 ]. Currently, the invasion and metastasis of PTC are the major cause of fatal outcome and, therefore, it is essential to elucidate the molecular mechanisms of PTC progression to facilitate the development of novel targeted therapies.…”

Section: Introductionmentioning

confidence: 99%

Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma

Zhou

Shan

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. Increasing evidence showed that microRNAs (miRNAs) play an important role in the PTC progression. In our study, the result showed that let-7a is significantly downregulated in PTC tissues and thyroid cancer cell lines. Overexpression of let-7a suppressed PTC cell proliferation, migration and invasion. Interestingly, we found that AKT2 was a direct target of let-7a and the expression levels of AKT2 were also observed to inversely correlate with let-7a expression in PTC tissues. Furthermore, enhancing AKT2 expression partially reversed the inhibitory effects of let-7a in PTC. Taken together, these findings suggest that let-7a acts as a novel suppressor by targeting the AKT2 gene and might be a candidate target for the development of novel therapeutic strategies to treat papillary thyroid carcinoma.

show abstract

Tumour‐to‐tumour metastasis from papillary thyroid carcinoma with BRAF mutation to lung adenocarcinoma with EGFR mutation: the utility of mutation‐specific antibodies

Abstract: As a component of multimodal diagnostic tools, immunohistochemistry can avoid some pitfalls involved in the molecular diagnosis of complicated cases (such as our own) and can help to ensure that patients receive optimal treatments.

Cited by 12 publications

References 13 publications

Metastases to the Thyroid Gland: What Can We Do?

Metastases to the Thyroid Gland: What Can We Do?

Metastasis to the Thyroid Gland: A Critical Review

Let-7a inhibits migration, invasion and tumor growth by targeting AKT2 in papillary thyroid carcinoma

Contact Info

Product

Resources

About